{"id":"NCT00299104","sponsor":"Genentech, Inc.","briefTitle":"A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis","officialTitle":"A Randomized, Phase 3, Controlled, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate (MTX) Compared to MTX Alone, in Methotrexate-Naive Patients With Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01","primaryCompletion":"2008-09","completion":"2013-07","firstPosted":"2006-03-06","resultsPosted":"2011-08-10","lastUpdate":"2017-07-28"},"enrollment":755,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"folate","otherNames":[]},{"type":"DRUG","name":"methotrexate","otherNames":[]},{"type":"DRUG","name":"methylprednisolone","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"rituximab","otherNames":[]}],"arms":[{"label":"Rituximab (0.5 g x 2) + Methotrexate","type":"EXPERIMENTAL"},{"label":"Rituximab (1.0 g x 2) + Methotrexate","type":"EXPERIMENTAL"},{"label":"Placebo + Methotrexate","type":"PLACEBO_COMPARATOR"}],"summary":"This is a phase III, randomized, controlled, double-blind, parallel group, international study in approximately 750 patients with active Rheumatoid Arthritis (RA) who are naive to Methotrexate (MTX) therapy. Rheumatoid Factor (RF)-positive and RF-negative patients will be enrolled and will be allocated equally between 3 treatment arms.","primaryOutcome":{"measure":"Change From Baseline in Modified Total Sharp Score (mTSS) From Screening at Week 52","timeFrame":"Baseline and week 52","effectByArm":[{"arm":"Placebo + Methotrexate","deltaMin":1.079,"sd":4.0934},{"arm":"Rituximab (0.5 g x 2) + Methotrexate","deltaMin":0.646,"sd":1.9196},{"arm":"Rituximab (1.0 g x 2) + Methotrexate","deltaMin":0.359,"sd":1.0095}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":"0.0016"},{"comp":"OG000 vs OG001","p":"0.1824"},{"comp":"OG000 vs OG002","p":"0.0004"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22012969","21557525","20937671"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":48,"n":249},"commonTop":["Infusion Related Reaction","Upper Respiratory Tract Infection","Nasopharyngitis","Nausea","Drug-Induced Liver Injury"]}}